Portal de Periódicos da CAPES

Reply to: “Comment on ‘Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes’”

2019; Elsevier BV; Volume: 88; Issue: 5 Linguagem: Inglês

10.1016/j.jaad.2019.03.006

1097-6787

Luca Schneller‐Pavelescu, Eduardo Vergara‐de Caso, A. Martorell, J. Romaní, Mireya Lázaro, Eva Vilarrasa, B. Díaz-Ley, I. Vázquez‐Osorio, Juan Manuel Segura Palacios, José Manuel Azaña Defez, Marcos A. González‐López, Javier Cañueto, Alejandro Molina‐Leyva, María Leiva-Salinas, F.J. Navarro‐Triviño, José Sánchez‐Payá, J.C. Pascual,

Microscopic Colitis

To the Editor: We appreciate the comments of Marasca et al1 on our article, "Interruption of Oral Clindamycin plus Rifampicin Therapy in Patients with Hidradenitis Suppurativa: An Observational Study to Assess Prevalence and Causes".2 There is little available evidence exploring treatment interruption and adverse events related to clindamycin plus rifampicin therapy, as shown in Table I.